Briakinumab

Commodity a leaf — nothing below it, 8 links to KBLI

Level: Commodity
Parent: 51202300
Below: 0
Links · KBLI: 8

Definition

UNSPSC 51202302

This classification denotes a monoclonal antibody with the molecular formula C6376H9874N1722O1992S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978I8M0P8X, more generally known as briakinumab. European Medicines Agency schedules briakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31454. The term BRIAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, No. 1, 2010 list 63. As of Q4 2014, BRIAKINUMAB remains US FDA's Preferred Term for this commodity.

Same parent

Under 51202300 · 6

51202301 Afelimomab Commodity 51202302 Briakinumab You are here 51202303 Penicillamine Commodity 51202304 Penicillamine disulfide Commodity 51202305 Penicillamine hydrochloride Commodity 51202306 Etanercept Commodity

Activities that produce or sell this

KBLI · 8

Inherited from family 51200000.

21012 Industri Produk Farmasi untuk Manusia Sub-class 21013 Industri Produk Farmasi untuk Hewan Sub-class 46441 Perdagangan Besar Sediaan Farmasi untuk Manusia Sub-class 46442 Perdagangan Besar Sediaan Farmasi untuk Hewan Sub-class 46902 Perdagangan Besar Berbagai Macam Barang Selain di Grosir/Perkulakan Swalayan Sub-class 47721 Perdagangan Eceran Sediaan Farmasi untuk Manusia di Apotek Sub-class 47722 Perdagangan Eceran Sediaan Farmasi untuk Manusia Selain di Apotek Sub-class 47726 Perdagangan Eceran Obat Farmasi untuk Hewan Sub-class

Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.